Bank of New York Mellon Corp - AIMMUNE THERAPEUTICS INC ownership

AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 129 filers reported holding AIMMUNE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.77 and the average weighting 0.9%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q3 2020$7,744,000
+99.3%
224,805
-3.3%
0.00%
+100.0%
Q2 2020$3,885,000
+16.4%
232,469
+0.5%
0.00%0.0%
Q1 2020$3,338,000
-85.0%
231,420
-65.1%
0.00%
-83.3%
Q4 2019$22,196,000
+7.7%
663,159
-32.6%
0.01%0.0%
Q3 2019$20,600,000
+177.2%
983,754
+175.6%
0.01%
+200.0%
Q2 2019$7,431,000
+61.9%
356,967
+73.9%
0.00%
+100.0%
Q1 2019$4,590,000
-65.3%
205,328
-62.9%
0.00%
-75.0%
Q4 2018$13,233,000
+183.6%
553,206
+223.4%
0.00%
+300.0%
Q3 2018$4,666,000
+1.0%
171,052
-0.4%
0.00%0.0%
Q2 2018$4,619,000
-7.9%
171,766
+9.1%
0.00%0.0%
Q1 2018$5,013,000
-0.8%
157,483
+17.9%
0.00%0.0%
Q4 2017$5,052,000
+51.4%
133,585
-0.8%
0.00%0.0%
Q3 2017$3,337,000
+23.6%
134,614
+2.5%
0.00%0.0%
Q2 2017$2,700,000
+10.6%
131,353
+16.9%
0.00%0.0%
Q1 2017$2,441,000
-12.4%
112,337
-17.5%
0.00%0.0%
Q4 2016$2,786,000
+104.9%
136,238
+50.3%
0.00%
Q3 2016$1,360,000
+52.0%
90,663
+9.7%
0.00%
Q2 2016$895,000
+28.4%
82,661
+60.8%
0.00%
Q1 2016$697,000
-15.2%
51,416
+15.4%
0.00%
Q4 2015$822,000
+23.2%
44,549
+69.1%
0.00%
Q3 2015$667,00026,3430.00%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q2 2019
NameSharesValueWeighting ↓
Foresite Capital Management II, LLC 3,967,900$42,933,00029.35%
TLP GROUP LLC 2,833,285$30,656,00020.86%
Aisling Capital LLC 2,990,000$32,352,0007.64%
Vivo Capital, LLC 763,009$8,256,0002.26%
RA Capital Management 1,292,940$13,990,0001.94%
Foresite Capital Management III, LLC 235,020$2,543,0001.74%
Palo Alto Investors LP 325,599$3,523,0000.27%
Rock Springs Capital Management LP 293,000$3,170,0000.24%
EMERALD MUTUAL FUND ADVISERS TRUST 332,625$3,599,0000.20%
Virtus ETF Advisers LLC 19,501$211,0000.16%
View complete list of AIMMUNE THERAPEUTICS INC shareholders